Théa Open Innovation and Galimedix announce strategic partnership to develop and commercialize GAL-101, a Phase 2/3-ready small molecule, to treat ophthalmic indications with high unmet medical need

Written by Julia Bittner on 29th March 2023. Posted in Client News.

• Previous
• Next